These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 24338217)
1. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577 [TBL] [Abstract][Full Text] [Related]
3. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. Buchler T; Pavlik T; Melichar B; Bortlicek Z; Usiakova Z; Dusek L; Kiss I; Kohoutek M; Benesova V; Vyzula R; Abrahamova J; Obermannova R BMC Cancer; 2014 May; 14():323. PubMed ID: 24884897 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D; Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901 [TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541 [TBL] [Abstract][Full Text] [Related]
9. MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. van Huis-Tanja LH; Gelderblom H; Punt CJ; Guchelaar HJ Pharmacogenet Genomics; 2013 Apr; 23(4):208-18. PubMed ID: 23407049 [TBL] [Abstract][Full Text] [Related]
10. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
11. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
12. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY; Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116 [TBL] [Abstract][Full Text] [Related]
14. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence. Lin PC; Lin HH; Lin JK; Lin CC; Yang SH; Li AF; Chen WS; Chang SC Int J Biol Markers; 2013 Jun; 28(2):182-6. PubMed ID: 23558935 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631 [TBL] [Abstract][Full Text] [Related]
16. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting. Moreau LC; Rajan R; Thirlwell MP; Alcindor T Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064 [TBL] [Abstract][Full Text] [Related]
18. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685 [TBL] [Abstract][Full Text] [Related]
19. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]